SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a polarizing CEO interview and market speculation regarding a proposed acquisition of eBay, leading to intense community debate over potential share dilution versus strategic growth. Shareholders are actively divided, with many analyzing the deal's financing math while others express frustration over the stock's volatility and the departure of high-profile institutional investors.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense community debate following a massive revenue beat and raised guidance that triggered significant price volatility rather than the expected breakout. While bulls highlight the company's compounding growth and dominant US commercial expansion, skeptics remain focused on concerns over high valuation, insider selling, and the sustainability of its government-linked business model.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing high volatility as investors track legislative progress on the Clarity Act, which aims to establish clear regulatory frameworks for stablecoin operations. The community remains focused on the potential impact of these rules on USDC's long-term utility and institutional integration compared to traditional financial infrastructure.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing significant volatility and trending sentiment as investors debate whether the current price represents a long-term value opportunity or a permanent decline for a struggling brand. While the community remains deeply divided, active discussions focus on recent insider buying from high-profile executives, ongoing concerns regarding market share loss to competitors, and speculative catalysts like upcoming global sporting events and potential tax tariff refunds.

AnySpend is a next-generation fiat on-ramp and swap platform built for the onchain economy. AnySpend sits at the center of a growing consumer and gaming ecosystem on Base. The platform connects traditional payment rails (ACH, card, and local bank transfers) directly to onchain liquidity via Caldera’s metalayer routing infrastructure, allowing users to instantly purchase, swap, or fund wallets across chains with a single transaction.

Anyswap

Sphere 3D is trending following the announcement of an all-stock merger with Cathedra Bitcoin, a move investors are viewing as a strategic expansion into data center infrastructure and high-performance computing. Market participants are actively discussing the potential synergies of the combined entity, including increased power capacity and hash rate, while monitoring technical support levels for signs of further momentum.

Sterling Infrastructure, Inc. engages in the provision of construction solutions. It operates through the following segments: Transportation Solutions, E-Infrastructure Solutions, and Building Solutions. The Transportation Solutions segment includes infrastructure and rehabilitation projects for highways, roads, bridges, airports, ports, light rail, water, wastewater, and storm drainage systems. The E-Infrastructure Solutions projects develop advanced, large-scale site development systems and services for data centers, e-commerce distribution centers, warehousing, transportation, energy, and more. The Building Solutions segment projects include residential and commercial concrete foundations for single-family and multi-family homes, parking structures, elevated slabs, and other concrete work. The company was founded in 1955 and is headquartered in The Woodlands, TX.

Sterling Infrastructure Inc

Sterling Construction Company, Inc.

Sterling Infrastructure is trending as investors digest record-breaking quarterly results and raised full-year guidance, highlighting the company's strong position within the mission-critical e-infrastructure and data center buildout. The community is actively discussing the stock's impressive trajectory driven by substantial backlog growth and successful strategic integrations, with many focusing on its role as a key player in domestic infrastructure expansion.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is trending as investors weigh explosive AI infrastructure demand and rapid global capacity expansion against concerns over governance issues and historical margin volatility heading into earnings. The community remains deeply divided between long-term bulls highlighting undervalued metrics and massive hiring velocity, and skeptics wary of potential management headwinds and past accounting controversies.

Insight Molecular Diagnostics, Inc. is a diagnostics technology company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The company was founded in September 2009 and is headquartered in Nashville, TN.

Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. ($IMDX) is trending due to strong institutional accumulation and positive developments surrounding the GraftAssure assay, with investors closely watching for an upcoming FDA catalyst. The community is actively discussing the stock's potential for significant adoption in the transplant diagnostics space, often highlighting recent insider buying as a signal of long-horizon conviction.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD is gaining traction following an official listing on Revolut and ongoing developments within the Rezolve AI ecosystem, which leverages the project's decentralized data indexing. Community discussion is polarized, with bulls highlighting the potential for long-term infrastructure growth and revenue pool utility, while skeptics express frustration over recent price volatility and concerns regarding tokenomics.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending following the announcement of a significant boardroom shakeup, where four long-standing directors resigned to make way for new independent members. Despite investor enthusiasm for these leadership changes and potential future growth, the stock remains under pressure from community concerns regarding high fuel costs, geopolitical tensions in the Middle East, and weak booking guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>BioLineRx partnered with Hemispherian to conduct a trial testing GLIX1 in patients with Glioblastoma.</li><li>Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable safety profile.</li><li>BioLineRx is currently testing Motixafortide in a Phase 2b trial for pancreatic cancer.</li></ul>Shares of BioLineRx Ltd. (BLRX) surged 10% in pre-market trading on Tuesday, putting the stock on track to test its 50-day moving average for the first time since early March, after the company hit a significant milestone by dosing the first patient in an early-stage trial of its new cancer therapy.BioLineRx has partnered with Hemispherian AS, a clinical-stage oncology firm, to conduct a trial testing GLIX1 in patients with Glioblastoma and other high-grade brain tumors.Meanwhile, retail sentiment for <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> on Stocktwits remained in the ‘neutral’ territory over the past 24 hours.<h2 class="st-heading-2">Initial Trial Results Expected In 2027</h2>GLIX1 is a first-in-class oral therapy designed to selectively damage cancer cells by restoring TET2 activity, a tumor suppressor gene. This novel approach could provide a new treatment option for aggressive tumors such as Glioblastoma, where effective therapies remain limited, BioLineRx said.Early preclinical data showed strong anti-tumor activity, good brain penetration, and a favorable safety profile. The Phase 1 trial will enroll up to 30 patients to determine a safe dose, with initial results expected in the first half of 2027.“We believe GLIX1 has the potential to offer a novel therapeutic approach in this cancer indication, as well as in multiple other cancer indications, where DNA damage repair is critical for cancer survival,” said Philip Serlin, CEO of BioLineRx.<h2 class="st-heading-2">What Else Is In The Pipeline?</h2>BioLineRx is testing Motixafortide in a Phase 2b trial for pancreatic cancer, combining it with immunotherapy and standard chemotherapy. The study is progressing quickly, with an interim analysis expected later this year.The company is also testing Motixafortide for Sickle Cell Disease (SCD) and gene therapy. A Phase 1 study showed the drug can help mobilize stem cells for gene therapy in sickle cell disease.The stock has shed 22% of its value so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-glnd-stock-crash-to-52-week-low-today/cZB8sI8Re5A">Why Did GLND Stock Crash 30% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

BLRX Stock Surges Pre-Market On Cancer Trial Catalyst – Eyes 50-DMA Breakout For First Time In Nearly 2 Months

The biotech firm announced the dosing of its first patient in an early-stage trial of its new cancer therapy.

Equity

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a...

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM...

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

BioLineRx Reports 2025 Financial Results and Provides Corporate Update BioLineRx Reports 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, March 23, 2026 - On track...

Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings

BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.read more...

BioLineRx to Report 2025 Annual Results on March 23, 2026

BioLineRx to Report 2025 Annual Results on March 23, 2026 BioLineRx to Report 2025 Annual Results on March 23, 2026 PR Newswire TEL AVIV, Israel, March 16, 2026 Management to Hold Conference Call at...

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel...

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 PR Newswire TEL AVIV, Israel, Nov. 18, 2025 Management to Hold...

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types BioLineRx Announces Receipt of USPTO Notice of Allowance for Key...

Shares of BioLineRx (BLRX) skyrocketed 32% on Friday after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-new-pilot-phase-data-phase-2-combination">announced</a> positive data from the single-arm pilot phase of its Phase 2 trial evaluating its drug in the treatment of pancreatic cancer.The study is evaluating the company’s Motixafortide, Cemiplimab, and standard-of-care chemotherapies Gemcitabine and Nab-paclitaxel, versus Gemcitabine and Nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. Progression-free means that the patient's disease did not get worse or spread.CEO Philip Serlin said that the data emerging from the pilot phase of the study are “extremely encouraging,” while also noting that pancreatic cancer is the “most challenging” tumor to treat.The company also stated that it now plans to enroll 108 patients in the Phase 2 trial, which will be a randomized study, based on the results of the pilot phase. The company had previously planned to enroll only 30 patients in the study.The trial is planned to be fully enrolled in 2027. While the trial's primary endpoint is progression-free survival (PFS), secondary objectives include safety, response rate, disease control rate, duration of clinical benefit, and overall survival.Following the news, Jones Research upgraded BioLineRx to ‘Buy’ from ‘Hold’ with a $12 price target. With these results, BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial, assuming favorable Phase II results, the analyst said.On Stocktwits, retail sentiment around BLRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_12_47_05_PM_png_ca2195fcbe.webp" alt="BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits" width="626" height="68"><figcaption>BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> is down by about 50% this year and by about 84% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-eyeing-hiv-drug-rollout-in-low-income-countries-report/ch0ubVvRbuE">Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating

The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Current Price	$3.04
Prev Close	$2.86
Open	$3.10
Dividend Yield	0.00%
50-Day Moving Average	$2.53
Beta	0.95
Avg. Volume	24,085.98
PE Ratio	-16.80

52-Week High	$7.77
52-Week Low	$2.15
Market Capitalization	$13.23M
EPS (Annual)	-$0.2903
Price to Book	0.73
Revenue Per Employee	$49,556.71

BLRX
BioLineRx, Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BLRX News

BLRXBioLineRx, Ltd.